Carvana has a ‘competitive moat' over CarMax. But don't sleep on CarMax's stock, Morgan Stanley says.

Morgan Stanley has slashed its price target on CarMax shares, questioning the used-car retailer's competitive viability against Carvana following a recent profit miss and 20% stock selloff. Despite acknowledging Carvana's significant "competitive moat" over CarMax, the firm still identifies potential upside for CarMax's stock, suggesting a nuanced outlook amidst increased industry competition.

Analysis

Morgan Stanley has materially revised its outlook on CarMax (KMX) following a recent profit miss that triggered a 20% selloff in the company's stock. The firm's analysis highlights significant concerns about CarMax's ability to compete effectively against Carvana (CVNA), which is perceived to hold a substantial "competitive moat." This competitive gap is so pronounced that analysts commented it is "hard to believe they're in the same industry," pointing to a fundamental divergence in their business models or execution. In response to these headwinds, Morgan Stanley has slashed its price target for KMX. However, despite the deeply negative assessment of its competitive positioning, the firm's note also suggests that the recent sharp stock decline may have created a valuation-based "upside," presenting a complex and somewhat contradictory view for investors.

Key Decisions for Investors

• Investors in CarMax (KMX) should weigh the potential for a valuation-driven rebound, as hinted by Morgan Stanley's 'upside' comment, against the severe competitive pressures and operational concerns that prompted the 20% selloff and price target cut.
• The explicit praise for Carvana's (CVNA) 'competitive moat' relative to CarMax's struggles could support a pairs trade strategy, going long CVNA and short KMX, to capitalize on the perceived divergence in performance.
• Monitor CarMax's next earnings release closely for any evidence of margin stabilization or a credible strategic response to the competitive threat, as this will be critical to validating the 'upside' thesis.